AFA
MYGN icon

Abacus FCF Advisors’s Myriad Genetics MYGN Stock Holding History

Abacus FCF Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$427K Buy
11,798
+1,728
+17% +$49.3K 1.33% 2
2017
Q2 		$260K Buy
10,070
+5,157
+105% +$109K 1.01% 40
2017
Q1 		$94K Buy
4,913
+2,312
+89% +$41K 0.78% 95
2016
Q4 		$43K Buy
2,601
+1,461
+128% +$26.4K 0.72% 100
2016
Q3 		$23K Buy
+1,140
New +$28.9K 0.92% 99

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Abacus FCF Advisors's MYGN Position: Q3 2017 in Review

Abacus FCF Advisors increased its Myriad Genetics (MYGN) stake by 17% in Q3 2017, buying an estimated $49.3K and bringing the position to 11,798 shares worth $427K. The position accounts for 1.33% of the portfolio, ranked #2.

Abacus FCF Advisors first reported a position in MYGN in Q3 2016 and has held it in 5 quarters since. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

  • Abacus FCF Advisors held 11,798 shares of Myriad Genetics worth $427K as of Q3 2017.
  • Abacus FCF Advisors bought 1,728 Myriad Genetics shares in Q3 2017, an estimated $49.3K.
  • Myriad Genetics made up 1.33% of Abacus FCF Advisors's portfolio in Q3 2017, its #2 holding.
  • Abacus FCF Advisors first reported a position in Myriad Genetics in Q3 2016 and has held it in 5 quarters since.
  • 220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on Abacus FCF Advisors's 13F filing for Q3 2017, filed 1 Dec 2017.